Online inquiry

IVTScrip™ mRNA-Human ADAMTS5, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK12504MR)

This product GTTS-WK12504MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADAMTS5 protein. This product can be used in Migration phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_007038.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 11096
UniProt ID Q9UNA0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADAMTS5, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK12504MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK22296MR IVTScrip™ mRNA-Human ARHGAP32, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARHGAP32
GTTS-WK27093MR IVTScrip™ mRNA-Human ARHGAP29, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARHGAP29
GTTS-WK17341MR IVTScrip™ mRNA-Human ANKUB1, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANKUB1
GTTS-WK22003MR IVTScrip™ mRNA-Human ARHGAP9, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP9
GTTS-WK16523MR IVTScrip™ mRNA-Human AHNAK2, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AHNAK2
GTTS-WK20965MR IVTScrip™ mRNA-Human ANXA7, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANXA7
GTTS-WK25583MR IVTScrip™ mRNA-Human ARHGAP15, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP15
GTTS-WK12900MR IVTScrip™ mRNA-Human Aggrecan, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Aggrecan
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW